Michigan 2025-2026 Regular Session Status: Passed Senate 1 D cosponsors

SB 3 — Health: pharmaceuticals; prescription drug cost and affordability review act; create. Creates new act.

Last action — referred to Committee on Government Operations

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill has passed the Senate. Introduced April 24, 2025. It now moves to the second chamber.

Next likely step: consideration and a floor vote in the House.

Odds of enactment

Moderate chance

Based on the sponsor, cosponsors, and committee posture, this bill has a moderate chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 48% · moderate confidence

  • Passed Senate

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (1 D).

  • Cleared a recorded vote

    Passed 2 recorded votes so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Health: pharmaceuticals; prescription drug cost and affordability review act; create. Creates new act.

Bill Text

What changed in the latest version

358 added · 356 removed

Plain-language change summary

The latest version of SB 3 includes a requirement for at least one board member to advocate for patients, ensuring that patient perspectives are considered in decisions. It also specifies that the governor cannot appoint individuals who have financial ties to manufacturers or are registered lobbyists, which is intended to reduce potential conflicts of interest. These changes are important as they aim to enhance transparency and accountability within the board, ultimately promoting better healthcare practices.

→
Previous
Latest
SUBSTITUTE FOR SENATE BILL NO.
SB-3, As Passed Senate, April 24, 2025 SUBSTITUTE FOR SENATE BILL NO.
(a) "Biologic" means a drug that is produced or distributed in EMR S00487'25 (S-1) pwb154 1 accordance with a biologics license application approved by the United States Food and Drug Administration.
(a) "Biologic" means a drug that is produced or distributed in EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 accordance with a biologics license application approved by the United States Food and Drug Administration.
(i) An insurer authorized under the insurance code of 1956, EMR S00487'25 (S-1) pwb154 1 1956 PA 218, MCL 500.100 to 500.8302, to deliver, issue for delivery, or renew in this state a health insurance policy.
(i) An insurer authorized under the insurance code of 1956, EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 1956 PA 218, MCL 500.100 to 500.8302, to deliver, issue for delivery, or renew in this state a health insurance policy.
(q) "Third-party payer" means a health insurer, a state department or agency administering a plan of medical assistance under the social welfare act, 1939 PA 280, MCL 400.1 to 400.119b, a EMR S00487'25 (S-1) pwb154 1 person administering a self-funded plan, or a pharmacy benefit manager.
(q) "Third-party payer" means a health insurer, a state department or agency administering a plan of medical assistance under the social welfare act, 1939 PA 280, MCL 400.1 to 400.119b, a EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 person administering a self-funded plan, or a pharmacy benefit manager.
At least 1 member of the board must be an individual who advocates for patients.
After the first appointments, the term of a member of the board is 4 years or EMR S00487'25 (S-1) pwb154 1 until a successor is appointed, whichever is later.
After the EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 first appointments, the term of a member of the board is 4 years or until a successor is appointed, whichever is later.
(10) The salaries and other expenses incurred by members of EMR S00487'25 (S-1) pwb154 1 the board are subject to an annual appropriation as provided by law.
EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 (10) The salaries and other expenses incurred by members of the board are subject to an annual appropriation as provided by law.
The mutual insurance company under this subparagraph must not be an entity that, directly or indirectly, through 1 or more intermediaries, controls, is controlled by, or is under common control with the managed care organization under subdivision (c)(iv).
The mutual insurance company under this subparagraph must not be an entity that, directly or indirectly, through 1 or more intermediaries, controls, is controlled by, or is under common control with the managed care organization under subdivision EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 (c)(iv).
EMR S00487'25 (S-1) pwb154 1 (vii) One member of the public.
(vii) One member of the public.
(vii) The public.
EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 (vii) The public.
EMR S00487'25 (S-1) pwb154 1 (3) The governor shall ensure that the members appointed to the council have knowledge in 1 or more of the following areas:
(3) The governor shall ensure that the members appointed to the council have knowledge in 1 or more of the following areas:
(9) The council shall conduct its business in compliance with the open meetings act, 1976 PA 267, MCL 15.261 to 15.275.
(9) The council shall conduct its business in compliance with EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 the open meetings act, 1976 PA 267, MCL 15.261 to 15.275.
EMR S00487'25 (S-1) pwb154 1 (10) Except as otherwise provided in this subsection, a writing that is prepared, owned, used, in the possession of, or retained by the council in performing an official function is subject to the freedom of information act, 1976 PA 442, MCL 15.231 to 15.246.
(10) Except as otherwise provided in this subsection, a writing that is prepared, owned, used, in the possession of, or retained by the council in performing an official function is subject to the freedom of information act, 1976 PA 442, MCL 15.231 to 15.246.
(c) The prescription drug product is a generic drug that, as adjusted annually for inflation in accordance with the Consumer Price Index, has a wholesale acquisition cost that meets both of the following requirements:
(c) The prescription drug product is a generic drug that, as adjusted annually for inflation in accordance with the Consumer Price Index, has a wholesale acquisition cost that meets both of EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 the following requirements:
EMR S00487'25 (S-1) pwb154 1 (i) Is $100.00 or more for any of the following:
(i) Is $100.00 or more for any of the following:
(4) If the board conducts a cost and affordability review of a EMR S00487'25 (S-1) pwb154 1 prescription drug product, the board may consider when conducting the review any document or research related to the manufacturer's selection of the introductory price or price increase of the prescription drug product, including life cycle management, net average price in this state, market competition, projected revenue, and, subject to subsection (7), the estimated cost effectiveness of the prescription drug product.
EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 (4) If the board conducts a cost and affordability review of a prescription drug product, the board may consider when conducting the review any document or research related to the manufacturer's selection of the introductory price or price increase of the prescription drug product, including life cycle management, net average price in this state, market competition, projected revenue, and, subject to subsection (7), the estimated cost effectiveness of the prescription drug product.
(d) The average monetary concession, discount, or rebate that another manufacturer provides or is expected to provide to health insurers and pharmacy benefit managers in this state for EMR S00487'25 (S-1) pwb154 1 therapeutic alternatives.
(d) The average monetary concession, discount, or rebate that another manufacturer provides or is expected to provide to health EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 insurers and pharmacy benefit managers in this state for therapeutic alternatives.
(a) Relevant administrative costs related to supplying or stocking the prescription drug product.
(a) Relevant administrative costs related to supplying or EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 stocking the prescription drug product.
EMR S00487'25 (S-1) pwb154 1 (b) The impact of an upper payment limit for the prescription drug product on 340B covered entities.
(b) The impact of an upper payment limit for the prescription drug product on 340B covered entities.
(1) Except as otherwise provided in subsection (2), if the board establishes an upper payment limit under section 11 for a prescription drug product intended for use by individuals in this state, beginning on the effective date of the upper payment limit, a prescription drug product purchaser or third-party payer shall not purchase, bill, or reimburse for the prescription drug EMR S00487'25 (S-1) pwb154 1 product in an amount that exceeds the upper payment limit, regardless of whether the prescription drug product is dispensed or distributed in person, by mail, or by other means.
(1) Except as otherwise provided in subsection (2), if the board establishes an upper payment limit under section 11 for a prescription drug product intended for use by individuals in this state, beginning on the effective date of the upper payment limit, a prescription drug product purchaser or third-party payer EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 shall not purchase, bill, or reimburse for the prescription drug product in an amount that exceeds the upper payment limit, regardless of whether the prescription drug product is dispensed or distributed in person, by mail, or by other means.
The state treasurer shall direct the investment of money in the fund and credit interest and earnings EMR S00487'25 (S-1) pwb154 1 from fund investments to the fund.
The state treasurer shall direct the EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps 1 investment of money in the fund and credit interest and earnings from fund investments to the fund.
(f) The impact of an upper payment limit on 340B covered EMR S00487'25 (S-1) pwb154 entities.
EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps (f) The impact of an upper payment limit on 340B covered entities.
Final Page EMR S00487'25 (S-1) pwb154
Final Page EMR S00487'25 (S-1)_SB3_APS_1 gqy2ps
⬇ Download PDF
View plain text versions (7)

Action History

  1. referred to Committee on Government Operations

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 146 not signed on · 15 voted No

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (146)

146 members have not signed on to this bill.

Show all 146 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

PASSED

Passed 20 Yea · 15 Nay · 2 Other
Party YeaNayPresentNot Voting
Democrat 19000
Republican 11402
Unaffiliated 0100
Total 201502
% of votes cast 54%41%0%5%
How each member voted (37)
Member Party Vote
Outman — Nay
Darrin Camilleri Democrat Yea
Dayna Polehanki Democrat Yea
Erika Geiss Democrat Yea
Jeff Irwin Democrat Yea
Jeremy Moss Democrat Yea
John Cherry Democrat Yea
Kevin Hertel Democrat Yea
Mallory McMorrow Democrat Yea
Mary Cavanagh Democrat Yea
Paul Wojno Democrat Yea
Rosemary Bayer Democrat Yea
Sam Singh Democrat Yea
Sarah Anthony Democrat Yea
Sean McCann Democrat Yea
Stephanie Chang Democrat Yea
Sue Shink Democrat Yea
Sylvia Santana Democrat Yea
Veronica Klinefelt Democrat Yea
Winnie Brinks Democrat Yea
Aric Nesbitt Republican Nay
Dan Lauwers Republican Nay
Edward McBroom Republican Nay
Jim Runestad Republican Nay
John Damoose Republican Yea
Jon Bumstead Republican Nay
Jonathan Lindsey Republican Nay
Joseph Bellino Jr. Republican Nay
Kevin Daley Republican Nay
Lana Theis Republican Not Voting
Mark Huizenga Republican Not Voting
Michael Webber Republican Nay
Michele Hoitenga Republican Nay
Roger Hauck Republican Nay
Roger Victory Republican Nay
Ruth Johnson Republican Nay
Thomas Albert Republican Nay

Official roll call →

PASSED ROLL CALL # 68 YEAS 20 NAYS 15 EXCUSED 1 NOT VOTING 1

Passed 20 Yea · 15 Nay · 2 Other
Party YeaNayPresentNot Voting
Democrat 19000
Republican 11502
Total 201502
% of votes cast 54%41%0%5%
How each member voted (37)
Member Party Vote
Darrin Camilleri Democrat Yea
Dayna Polehanki Democrat Yea
Erika Geiss Democrat Yea
Jeff Irwin Democrat Yea
Jeremy Moss Democrat Yea
John Cherry Democrat Yea
Kevin Hertel Democrat Yea
Mallory McMorrow Democrat Yea
Mary Cavanagh Democrat Yea
Paul Wojno Democrat Yea
Rosemary Bayer Democrat Yea
Sam Singh Democrat Yea
Sarah Anthony Democrat Yea
Sean McCann Democrat Yea
Stephanie Chang Democrat Yea
Sue Shink Democrat Yea
Sylvia Santana Democrat Yea
Veronica Klinefelt Democrat Yea
Winnie Brinks Democrat Yea
Aric Nesbitt Republican Nay
Dan Lauwers Republican Nay
Edward McBroom Republican Nay
Jim Runestad Republican Nay
John Damoose Republican Yea
Jon Bumstead Republican Nay
Jonathan Lindsey Republican Nay
Joseph Bellino Jr. Republican Nay
Kevin Daley Republican Nay
Lana Theis Republican Not Voting
Mark Huizenga Republican Not Voting
Michael Webber Republican Nay
Michele Hoitenga Republican Nay
Rick Outman Republican Nay
Roger Hauck Republican Nay
Roger Victory Republican Nay
Ruth Johnson Republican Nay
Thomas Albert Republican Nay

Official roll call →

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 3 do?
Health: pharmaceuticals; prescription drug cost and affordability review act; create. Creates new act.
Who sponsors SB 3?
SB 3 is sponsored by Darrin Camilleri (Democrat).
What is the current status of SB 3?
This bill has passed the Senate. Introduced April 24, 2025. It now moves to the second chamber.
Where can I track SB 3?
Track SB 3 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 3

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 3

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →